A lawsuit against Group Health surfaces as the White House promotes Medicare Advantage for seniors.
The Freedom of Information Act lawsuit could spur the Centers for Medicare & Medicaid Services to release audits that document up to $650 million in overcharges.
Tennessee company’s Medicare billings for urine tests were examined by Kaiser Health News in 2017.
Amid an overall crackdown on private insurers’ Medicare billing practices, a new government audit and a whistleblower suit allege St. Louis-based Essence Group Holdings Corp.’s Medicare Advantage plans overcharged taxpayers.
An enhanced government effort to catch insurers that overcharge Medicare faces resistance from the insurance industry.
Giving consumers more knowledge about the costs of care has long been desired, but administration officials cautioned it could take two years or more for useful data to appear in a phone app.
Whistleblower lawsuits accuse Tennessee chain of bilking millions from Medicare for unnecessary urine drug tests.
Sen. Lamar Alexander (R-Tenn.), head of the influential HELP committee, wants to make it easier to share and store detailed medical histories.
In an interview, FDA Commissioner Scott Gottlieb reacts to a KHN/Fortune investigation of the drawbacks and risks of electronic health records.
The U.S. government claimed that ditching paper medical charts for electronic records would make health care better, safer and cheaper. Ten years and $36 billion later, the digital revolution has gone awry.
The U.S. government claimed that turning American medical charts into electronic records would make health care better, safer and cheaper. Ten years and $36 billion later, the system is an unholy mess. Inside a digital revolution that took a bad turn.
A DaVita subsidiary will pay $270 million over allegations that it cheated the federal government for years.
No one tracks sepsis cases closely enough to know how often these severe infections turn fatal. But the toll — both human and financial — is enormous, finds an investigation by KHN and the Chicago Tribune.
Post-9/11, Giuliani Partners helped craft a plan that put a halt to a probe into Purdue’s marketing of OxyContin.
Through a widely circulated brochure and a videotape of testimonials, the maker of OxyContin stressed patients’ right to opioid treatment for pain.
Fentanyl and other painkillers marketed as safer than Purdue Pharma’s blockbuster drug left their own trail of overdose deaths.
Did OxyContin maker admit opioids can be dangerous even when patients take them as prescribed — then walk it back?
The CEO of Comprehensive Pain Specialists was indicted in April. Now the group is closing clinics across several states.
An inside look at how Purdue Pharma pushed OxyContin despite risks of addiction and fatalities.
Esta historia forma parte de una serie en la que KHN investigará cuentas médicas sorprendentes enviadas por los usuarios.